¶ MAPT Gene Variants and Mutations
The MAPT (Microtubule-Associated Protein Tau) gene encodes the tau protein, which plays a critical role in microtubule stabilization and neuronal function. Mutations in MAPT are a major cause of frontotemporal dementia and related neurodegenerative disorders, including Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). [@hutton1998][@spillantini1998]
| Property |
Value |
| Gene Symbol |
MAPT |
| Full Name |
Microtubule-Associated Protein Tau |
| Chromosomal Location |
17q21.31 |
| NCBI Gene ID |
4137 |
| OMIM |
157140 |
| Ensembl ID |
ENSG00000186868 |
| UniProt ID |
P10636 |
| Inheritance |
Autosomal Dominant |
| Exons |
16 (major isoform transcripts) |
| Protein Length |
352-441 amino acids (6 isoforms) |
The MAPT gene produces the tau protein, which is primarily expressed in neurons. Tau functions to:
- Stabilize microtubules: Tau binds to microtubules and promotes their assembly and stability, essential for axonal transport
- Regulate axonal transport: By modulating microtubule dynamics, tau facilitates the trafficking of organelles and vesicles along axons
- Signal transduction: Tau interacts with various signaling molecules and participates in neuronal signaling pathways [@ballatore2007][@leybns2022]
The tau protein has six isoforms ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. Inclusion of exon 10 results in 3-repeat (3R) tau isoforms, while exclusion produces 4-repeat (4R) isoforms. The 4R/3R balance is critical for normal neuronal function. [@wang2024]
Mutations in MAPT cause a group of clinically and pathologically heterogeneous disorders collectively termed frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). These include: [@ghetti2015]
- Frontotemporal Dementia (FTD) — The most common cause of early-onset dementia, characterized by behavioral changes and language impairment
- Progressive Supranuclear Palsy (PSP) — A disorder causing vertical gaze palsy, parkinsonism, and cognitive decline [@spillantini1998]
- Corticobasal Degeneration (CBD) — Features include asymmetric rigidity, apraxia, and cortical sensory loss
- Pick's Disease — A form of FTD with characteristic Pick bodies (tau inclusions)
The MAPT gene exists in two major haplotypes: H1 and H2. The H1 haplotype is the ancestral form and is strongly associated with increased risk of PSP and CBD. The H1 haplotype spans a region including the MAPT gene and surrounding sequences, creating specific linkage disequilibrium patterns. [@caim2022]
- H1/H1 genotype: Increases risk of PSP by 3-5 fold, CBD by 2-3 fold
- H2 haplotype: More common in European populations, associated with reduced PSP risk
| Mutation |
Exon |
Effect |
Phenotype |
| P301L |
10 |
4R tau increase |
PSP, FTD |
| P301S |
10 |
4R tau increase |
FTD |
| G272V |
9 |
Tau dysfunction |
FTD |
| R406W |
13 |
Tau dysfunction |
FTD, AD |
| V337M |
12 |
Tau dysfunction |
FTD |
| K257T |
9 |
Tau dysfunction |
FTD |
| S305S |
10 |
4R tau increase |
FTD |
| R5H |
1 |
Aggregation |
Infantile ND |
| K369I |
11 |
Tau dysfunction |
FTD (British) |
The P301L mutation is one of the most common pathogenic MAPT mutations, causing PSP-like phenotype. [@chen2025]
MAPT mutations cause neurodegeneration through several mechanisms: [@ballatore2007][@chen2025][@wang2024]
- Tau aggregation: Mutations promote the formation of toxic tau oligomers and fibrils
- Phase separation: Mutant tau undergoes aberrant liquid-liquid phase separation, forming aggregates
- Altered splicing: Exon 10 mutations affect the ratio of 3R to 4R tau isoforms
- Microtubule dysfunction: Reduced tau-mediated microtubule stabilization impairs axonal transport
- Neuroinflammation: Tau pathology triggers inflammatory responses in glial cells
MAPT is predominantly expressed in the central nervous system, with highest levels in:
- Cerebral cortex — Particularly frontal and temporal lobes (affected in FTD)
- Hippocampus — Critical for memory (affected in AD)
- Basal ganglia — Including substantia nigra (affected in PSP and PD)
- Brainstem — Including structures involved in eye movements
Expression is neuron-specific, with minimal expression in glial cells under normal conditions.
- Tau aggregation inhibitors: Small molecules targeting tau fibril formation
- Microtubule stabilizers: Compounds like epothilone D to compensate for tau loss
- Anti-tau antibodies: Immunotherapies targeting extracellular tau
- Kinase inhibitors: Drugs targeting tau-phosphorylating kinases (GSK-3beta, CDK5)
- Gene therapy: Approaches to reduce mutant tau expression
- Tau degradation: Enhancing clearance of pathological tau via autophagy or proteasome
- Splice-modulating therapies: Correcting exon 10 splicing abnormalities
- Phase separation modulators: Preventing aberrant LLPS of tau